Literature DB >> 8200997

Multiple lipolysis defects in the insulin resistance (metabolic) syndrome.

S Reynisdottir1, K Ellerfeldt, H Wahrenberg, H Lithell, P Arner.   

Abstract

Bearing in mind the importance of upper-body obesity for the insulin resistance (or metabolic) syndrome and the abnormalities in free fatty acid metabolism associated with this disorder, the regulation of lipolysis in isolated subcutaneous adipocytes was investigated in 13 72-yr old upper-body obese men with insulin resistance and glucose intolerance and in 10 healthy 72-yr-old men. There was a marked resistance to the lipolytic effect of noradrenaline in the metabolic syndrome due to defects at two different levels in the lipolytic cascade. First, an 80-fold decrease in sensitivity to the beta 2-selective agonist terbutaline (P < 0.001) which could be ascribed to a 50% reduced number of beta 2-receptors (P < 0.005) as determined with radioligand binding. The groups did not differ as regards dobutamine (beta 1) or clonidine (alpha-2) sensitivity, nor beta 1-receptor number. The mRNA levels for beta 1- and beta 2-receptors were similar in the two groups. Second, the maximum stimulated lipolytic rate was markedly reduced in the metabolic syndrome. This was true for isoprenaline (nonselective beta-agonist), forskolin (activating adenylyl cyclase), and dibutyryl cAMP (activating protein kinase). In regression analysis, the observed abnormalities in lipolysis regulation correlated in an independent way with the degree of glucose intolerance (r = -0.67) and beta 2-receptor number with insulin resistance (r = 0.67). In conclusion, the results of this study indicate the existence of lipolytic resistance to catecholamines in the adipose tissue of elderly men with the metabolic syndrome, which may be of importance for impaired insulin action and glucose intolerance. The resistance is located at a posttranscriptional level of beta 2-receptor expression and at the protein kinase-hormone sensitive lipase level.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8200997      PMCID: PMC294492          DOI: 10.1172/JCI117271

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  42 in total

1.  Insulin resistance is a characteristic feature of primary hypertension independent of obesity.

Authors:  T Pollare; H Lithell; C Berne
Journal:  Metabolism       Date:  1990-02       Impact factor: 8.694

2.  Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species.

Authors:  D Langin; M P Portillo; J S Saulnier-Blache; M Lafontan
Journal:  Eur J Pharmacol       Date:  1991-07-09       Impact factor: 4.432

3.  Beta-adrenoceptor expression in human fat cells from different regions.

Authors:  P Arner; L Hellström; H Wahrenberg; M Brönnegård
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

Review 4.  The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy.

Authors:  H R Black
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

Review 5.  Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.

Authors:  R A DeFronzo; E Ferrannini
Journal:  Diabetes Care       Date:  1991-03       Impact factor: 19.112

6.  Expression of three human beta-adrenergic-receptor subtypes in transfected Chinese hamster ovary cells.

Authors:  K M Tate; M M Briend-Sutren; L J Emorine; C Delavier-Klutchko; S Marullo; A D Strosberg
Journal:  Eur J Biochem       Date:  1991-03-14

7.  Multiple defects in muscle glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus.

Authors:  A W Thorburn; B Gumbiner; F Bulacan; G Brechtel; R R Henry
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

Review 8.  Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension.

Authors:  M Modan; H Halkin
Journal:  Diabetes Care       Date:  1991-06       Impact factor: 19.112

9.  Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects.

Authors:  P Arner; T Pollare; H Lithell
Journal:  Diabetologia       Date:  1991-07       Impact factor: 10.122

Review 10.  Obesity, metabolism, and hypertension.

Authors:  L Landsberg
Journal:  Yale J Biol Med       Date:  1989 Sep-Oct
View more
  45 in total

Review 1.  Is the hypothalamic-pituitary-adrenal axis really hyperactivated in visceral obesity?

Authors:  P G Kopelman
Journal:  J Endocrinol Invest       Date:  1999-01       Impact factor: 4.256

2.  Lipolysis defect in white adipose tissue and rapid weight regain.

Authors:  Michal Kasher-Meron; Dou Y Youn; Haihong Zong; Jeffery E Pessin
Journal:  Am J Physiol Endocrinol Metab       Date:  2019-04-09       Impact factor: 4.310

Review 3.  Mediators of sympathetic activation in metabolic syndrome obesity.

Authors:  Nora E Straznicky; Nina Eikelis; Elisabeth A Lambert; Murray D Esler
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 4.  Adapting to obesity with adipose tissue inflammation.

Authors:  Shannon M Reilly; Alan R Saltiel
Journal:  Nat Rev Endocrinol       Date:  2017-08-11       Impact factor: 43.330

Review 5.  MicroRNAs in dysfunctional adipose tissue: cardiovascular implications.

Authors:  Basak Icli; Mark W Feinberg
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

6.  Quantifying size and number of adipocytes in adipose tissue.

Authors:  Sebastian D Parlee; Stephen I Lentz; Hiroyuki Mori; Ormond A MacDougald
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

Review 7.  Neural innervation of white adipose tissue and the control of lipolysis.

Authors:  Timothy J Bartness; Yang Liu; Yogendra B Shrestha; Vitaly Ryu
Journal:  Front Neuroendocrinol       Date:  2014-04-13       Impact factor: 8.606

8.  Coordinated transcriptional control of adipocyte triglyceride lipase (Atgl) by transcription factors Sp1 and peroxisome proliferator-activated receptor γ (PPARγ) during adipocyte differentiation.

Authors:  Debasish Roy; Kenneth T Farabaugh; Jing Wu; Alyssa Charrier; Cynthia Smas; Maria Hatzoglou; Kavitha Thirumurugan; David A Buchner
Journal:  J Biol Chem       Date:  2017-07-18       Impact factor: 5.157

9.  Defective fasting-induced PKA activation impairs adipose tissue glycogen degradation in obese Zucker rats.

Authors:  Marcelo Flores-Opazo; Jennifer Trieu; Timur Naim; Denisse Valladares-Ide; Hermann Zbinden-Foncea; David Stapleton
Journal:  Int J Obes (Lond)       Date:  2019-01-31       Impact factor: 5.095

10.  Adipocyte lipolysis in normal weight subjects with obesity among first-degree relatives.

Authors:  L Hellström; D Langin; S Reynisdottir; M Dauzats; P Arner
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.